Drug Discovery Technologies Market Growth Trajectory Through 2024-2033

The Drug Discovery Technologies Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Drug Discovery Technologies Market:
https://www.thebusinessresearchcompany.com/report/drug-discovery-technologies-global-market-report

According to The Business Research Company’s Drug Discovery Technologies Global Market Report 2024, The drug discovery technologies market size has grown rapidly in recent years. It will grow from $66.08 billion in 2023 to $72.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to growth in genomic and proteomic research, increased understanding of molecular biology, expansion of combinatorial chemistry, adoption of bioinformatics and computational approaches, rise of targeted therapies
.

The drug discovery technologies market size is expected to see rapid growth in the next few years. It will grow to $108.31 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to adoption of crispr for gene editing, expansion of precision medicine approaches, application of omics technologies in drug development, utilization of quantum computing in drug discovery, rise of patient-derived xenograft (pdx) models. Major trends in the forecast period include advancements in high-throughput screening, development of automated laboratory equipment, collaboration between academic and industry research, technological advances in imaging and microscopy, integration of artificial intelligence in drug discovery, 3d cell culture technologies, adoption of machine learning in drug design, collaboration between pharma companies and tech startups, integration of blockchain for data security.

The rising prevalence of acute and chronic diseases is expected to propel the drug discovery technologies market going forward. Chronic diseases last one year or more and require ongoing medical attention. Innovation in drug discovery technologies and drug development has brought many new treatments for chronic diseases. Integrating new and powerful emerging technologies, including digital health tools, AI, and machine learning, throughout the drug R&D process offers opportunities to address critical barriers and streamline clinical trials for prevalent chronic diseases. For instance, in May 2023, according to The United Nations (UN), a US-based intergovernmental organization to promote international cooperation and maintain international peace and security, Chronic diseases were responsible for seven out of 10 deaths in the US, killing more than 1.7 million Americans annually. Therefore, the rising prevalence of acute and chronic diseases will drive the drug discovery technologies market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12715&type=smp

The drug discovery technologies market covered in this report is segmented –

1) By Technology: High Throughput Screening, Genomics, Nanotechnology, Bioinformatics, Combinational Chemistry, Pharmacogenomics, Biochips, Bioanalytical Instruments, Ribonucleic Acid Interface (RNAI)
2) By Drug Type: Small Molecule Drugs, Biologic Drugs
3) By Disease Application: Cancer Diseases, Immunological Diseases, Neurological Diseases, Cardiovascular Diseases, Other Disease Applications
4) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End-Users

The invention of advanced technologies is a key trend in the drug discovery technologies market. Major companies operating in the drug discovery technologies market are launching advanced technologies to sustain their position in the market. For instance, in May 2023, Google LLC, a US-based technology company, launched Target and Lead Identification Suite, an AI-based tool to accelerate drug discovery. It is made to assist businesses in foreseeing and comprehending protein structure, a crucial aspect of drug research. The Suite will assist researchers in ingesting, storing, analyzing, and sharing vast volumes of genetic data. The new suites will help businesses save statistically significant amounts of time and money through the drug development process. They will contribute to resolving a long-standing problem in the biopharmaceutical sector.

The drug discovery technologies market report table of contents includes:

1. Executive Summary
2.Drug Discovery Technologies Market Characteristics
3.Drug Discovery Technologies Market Trends And Strategies
4.Drug Discovery Technologies Market analyis
5.Drug Discovery Technologies Market Size And Growth
6.Drug Discovery Technologies Segmentation
7. Drug Discovery TechnologiesRegional And Country Analysis
.
.
.
27.Drug Discovery Technologies Competitive Landscape And Company Profiles
28.Drug Discovery Technologies Key Mergers And Acquisitions
29.Drug Discovery Technologies Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• F. Hoffmann-La Roche AG
• Novartis AG
• Thermo Fisher Scientific Inc.
• AstraZeneca plc.
• Merck KGaA
• GE HealthCare Technologies Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model